These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

240 related items for PubMed ID: 27550943

  • 1. A Novel Polyphenol Conjugate Sensitizes Cisplatin-Resistant Head and Neck Cancer Cells to Cisplatin via Nrf2 Inhibition.
    Kim EH, Jang H, Roh JL.
    Mol Cancer Ther; 2016 Nov; 15(11):2620-2629. PubMed ID: 27550943
    [Abstract] [Full Text] [Related]

  • 2. Targeting Nrf2 with wogonin overcomes cisplatin resistance in head and neck cancer.
    Kim EH, Jang H, Shin D, Baek SH, Roh JL.
    Apoptosis; 2016 Nov; 21(11):1265-1278. PubMed ID: 27544755
    [Abstract] [Full Text] [Related]

  • 3. Nrf2 inhibition reverses the resistance of cisplatin-resistant head and neck cancer cells to artesunate-induced ferroptosis.
    Roh JL, Kim EH, Jang H, Shin D.
    Redox Biol; 2017 Apr; 11():254-262. PubMed ID: 28012440
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Induction of ferroptotic cell death for overcoming cisplatin resistance of head and neck cancer.
    Roh JL, Kim EH, Jang HJ, Park JY, Shin D.
    Cancer Lett; 2016 Oct 10; 381(1):96-103. PubMed ID: 27477897
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Targeting acid ceramidase sensitises head and neck cancer to cisplatin.
    Roh JL, Park JY, Kim EH, Jang HJ.
    Eur J Cancer; 2016 Jan 10; 52():163-72. PubMed ID: 26687835
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. TNFAIP2 confers cisplatin resistance in head and neck squamous cell carcinoma via KEAP1/NRF2 signaling.
    Xu T, Yang Y, Chen Z, Wang J, Wang X, Zheng Y, Wang C, Wang Y, Zhu Z, Ding X, Zhou J, Li G, Zhang H, Zhang W, Wu Y, Song X.
    J Exp Clin Cancer Res; 2023 Aug 01; 42(1):190. PubMed ID: 37525222
    [Abstract] [Full Text] [Related]

  • 19. The p53-reactivating small-molecule RITA enhances cisplatin-induced cytotoxicity and apoptosis in head and neck cancer.
    Roh JL, Ko JH, Moon SJ, Ryu CH, Choi JY, Koch WM.
    Cancer Lett; 2012 Dec 01; 325(1):35-41. PubMed ID: 22634494
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.